Redmile Group, LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Redmile Group, LLC reported 35 stock positions worth $1.5 billion. Its top holding was Scholar Rock (SRRK) at 29.5% of the portfolio, followed by Krystal Biotech (KRYS, 11.5%) and Stoke Therapeutics (STOK, 9.0%). Compared with Q4 2025, it opened 5 new positions, sold out of 4, added to 6 and reduced 16. The biggest buy was Scholar Rock (SRRK, shares +74%) and the biggest sale Nurix Therapeutics (NRIX, shares −4%).
- Most Recent 13F
- Q2 2026
- Location
- LARKSPUR, CA
- CIK
- 0001425738
- Portfolio Value
- $1.5B (Q1 2026)
- SEC Filing
- 0001104659-26-062579 ↗ filed May 15, 2026
Holdings Value
Holdings 35 stocks · $1.5B
| SRRK Scholar Rock Holding Corp. | 29.51% | 9,066,621 | $445.7M | Add +73.7% |
| KRYS Krystal Biotech Inc. | 11.52% | 673,505 | $174.0M | Reduce -0.6% |
| STOK Stoke Therapeutics Inc. | 8.98% | 4,164,120 | $135.6M | Add +3.2% |
| IMNM Immunome Inc. | 8.05% | 5,558,885 | $121.6M | Reduce -2.8% |
| NRIX Nurix Therapeutics Inc. | 7.94% | 7,732,808 | $119.9M | Reduce -4.5% |
| ANNX Annexon Inc. | 5.34% | 14,549,768 | $80.6M | Add +44.8% |
| ADCT Adc Therapeutics SA | 3.84% | 15,470,502 | $58.0M | Reduce -1.3% |
| RGNX Regenxbio Inc. | 2.42% | 4,368,804 | $36.6M | No change |
| STTK Shattuck Labs Inc. | 2.36% | 5,539,724 | $35.6M | No change |
| BEAM Beam Therapeutics Inc. | 1.95% | 1,237,659 | $29.5M | Reduce -3.8% |
| NGNE Neurogene Inc. | 1.95% | 1,459,599 | $29.4M | No change |
| COGT Cogent Biosciences Inc. | 1.75% | 688,036 | $26.5M | Reduce -52.1% |
| ABSI Absci Corp. | 1.64% | 8,253,316 | $24.8M | No change |
| IDYA Ideaya Biosciences Inc. | 1.15% | 521,117 | $17.4M | Reduce -29.8% |
| ALXO Alx Oncology Holdings Inc. | 1.06% | 7,964,188 | $16.0M | Add +143.9% |
| FATE Fate Therapeutics Inc. | 1.02% | 12,872,946 | $15.4M | No change |
| XENE Xenon Pharmaceuticals Inc. | 1.01% | 262,674 | $15.3M | Add +96.2% |
| SLDB Solid Biosciences Inc. | 0.96% | 2,011,895 | $14.5M | Add +8.1% |
| NUVB Nuvation Bio Inc. | 0.90% | 3,153,256 | $13.5M | Reduce -0.3% |
| ZYME Zymeworks Inc. | 0.82% | 491,654 | $12.3M | No change |
| SLN Silence Therapeutics PLC-ADR | 0.76% | 2,164,777 | $11.4M | No change |
| DBVT DBV Technologies SA-Spon ADR | 0.68% | 491,340 | $10.3M | Reduce -10.6% |
| BMRN Biomarin Pharmaceutical Inc. | 0.65% | 173,859 | $9.8M | New |
| CLDX Celldex Therapeutics Inc. | 0.55% | 261,508 | $8.3M | Reduce -7.7% |
| CBLL Ceribell Inc. | 0.47% | 386,786 | $7.1M | Reduce -11.1% |
| LIVN Livanova PLC | 0.46% | 108,354 | $6.9M | Reduce -8.2% |
| ESTA Establishment Labs Holdings | 0.39% | 103,464 | $5.9M | Reduce -8.2% |
| PRME Prime Medicine Inc. | 0.37% | 1,590,832 | $5.5M | New |
| ORIC Oric Pharmaceuticals Inc. | 0.35% | 415,710 | $5.3M | Reduce -7.2% |
| EPRX Eupraxia Pharmaceuticals Inc. | 0.34% | 700,000 | $5.1M | New |
| ARDX Ardelyx Inc. | 0.29% | 733,350 | $4.4M | New |
| IVVD Invivyd Inc. | 0.23% | 2,648,659 | $3.4M | Reduce -1.2% |
| ATRA Atara Biotherapeutics Inc. | 0.14% | 441,701 | $2.1M | No change |
| AGMB Agomab Therapeutics NV | 0.11% | 156,250 | $1.6M | New |
| PLRX Pliant Therapeutics Inc. | 0.06% | 772,126 | $973K | Reduce -52.2% |
Portfolio Sells Q4 2025 → Q1 2026
| NRIX Nurix Therapeutics Inc. | Reduce -4.5% | 7.94% | −3.37 |
| RAPT Rapt Therapeutics Inc. | Sold out | 0.00% | −2.21 |
| COGT Cogent Biosciences Inc. | Reduce -52.1% | 1.75% | −2.01 |
| NUVB Nuvation Bio Inc. | Reduce -0.3% | 0.90% | −1.19 |
| IMNM Immunome Inc. | Reduce -2.8% | 8.05% | −1.00 |
| REPL Replimune Group Inc. | Sold out | 0.00% | −0.79 |
| KRYS Krystal Biotech Inc. | Reduce -0.6% | 11.52% | −0.78 |
| IDYA Ideaya Biosciences Inc. | Reduce -29.8% | 1.15% | −0.74 |
| BEAM Beam Therapeutics Inc. | Reduce -3.8% | 1.95% | −0.67 |
| RPTX Repare Therapeutics Inc. | Sold out | 0.00% | −0.30 |
| IVVD Invivyd Inc. | Reduce -1.2% | 0.23% | −0.26 |
| CBLL Ceribell Inc. | Reduce -11.1% | 0.47% | −0.23 |
| ADCT Adc Therapeutics SA | Reduce -1.3% | 3.84% | −0.23 |
| ESTA Establishment Labs Holdings | Reduce -8.2% | 0.39% | −0.22 |
| DBVT DBV Technologies SA-Spon ADR | Reduce -10.6% | 0.68% | −0.10 |
| PLRX Pliant Therapeutics Inc. | Reduce -52.2% | 0.06% | −0.08 |
| LIVN Livanova PLC | Reduce -8.2% | 0.46% | −0.08 |
| KLRS Kalaris Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| CLDX Celldex Therapeutics Inc. | Reduce -7.7% | 0.55% | −0.02 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -7.2% | 0.35% | +0.08 |
Portfolio Buys Q4 2025 → Q1 2026
| SRRK Scholar Rock Holding Corp. | Add +73.7% | 29.51% | +12.58 |
| ANNX Annexon Inc. | Add +44.8% | 5.34% | +1.62 |
| ALXO Alx Oncology Holdings Inc. | Add +143.9% | 1.06% | +0.79 |
| BMRN Biomarin Pharmaceutical Inc. | New | 0.65% | +0.65 |
| XENE Xenon Pharmaceuticals Inc. | Add +96.2% | 1.01% | +0.57 |
| PRME Prime Medicine Inc. | New | 0.37% | +0.37 |
| EPRX Eupraxia Pharmaceuticals Inc. | New | 0.34% | +0.34 |
| ARDX Ardelyx Inc. | New | 0.29% | +0.29 |
| SLDB Solid Biosciences Inc. | Add +8.1% | 0.96% | +0.19 |
| AGMB Agomab Therapeutics NV | New | 0.11% | +0.11 |
| STOK Stoke Therapeutics Inc. | Add +3.2% | 8.98% | −0.45 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q1 2026 | 35 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q4 2025 | 34 | $1.4B | SRRK, KRYS, NRIX, STOK, IMNM |
| Q3 2025 | 40 | $1.0B | SRRK, KRYS, STOK, ZYME, ADCT |
| Q2 2025 | 48 | $939.6M | SRRK, KRYS, ZYME, STOK, IMNM |
| Q1 2025 | 56 | $1.1B | SRRK, KRYS, FOLD, ZYME, NRIX |
| Q4 2024 | 62 | $1.4B | SRRK, KRYS, NRIX, ZYME, FOLD |
| Q3 2024 | 63 | $1.7B | KRYS, NRIX, FOLD, IMNM, KYMR |
| Q2 2024 | 63 | $1.7B | KRYS, FOLD, NRIX, STOK, IMNM |
| Q1 2024 | 77 | $2.7B | KRYS, FOLD, IMNM, SRRK, FATE |